369 SOUTH SAN ANTONIO RD., LOS ALTOS, CA
Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
Announces $120 Million Private Placement Financing
Reports Full Year 2025 Financial Results and Recent Business Highlights
Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Changes in Board, Management or Compensation
Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Definitive Revised Proxy Statement